Intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion disease
Mesenchymal stromal cells (MSCs) are an intriguing avenue for the treatment of neurological disorders due to their ability to migrate to sites of neuroinflammation and respond to paracrine signaling in those sites by secreting cytokines, growth factors, and other neuromodulators. We potentiated this...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2023.1158408/full |
| _version_ | 1827949693076766720 |
|---|---|
| author | Arielle J. D. Hay Arielle J. D. Hay Amanda S. Latham Amanda S. Latham Genova Mumford Genova Mumford Amelia D. Hines Amelia D. Hines Sydney Risen Sydney Risen Elizabeth Gordon Connor Siebenaler Connor Siebenaler Vincenzo S. Gilberto Vincenzo S. Gilberto Mark D. Zabel Mark D. Zabel Mark D. Zabel Julie A. Moreno Julie A. Moreno Julie A. Moreno Julie A. Moreno |
| author_facet | Arielle J. D. Hay Arielle J. D. Hay Amanda S. Latham Amanda S. Latham Genova Mumford Genova Mumford Amelia D. Hines Amelia D. Hines Sydney Risen Sydney Risen Elizabeth Gordon Connor Siebenaler Connor Siebenaler Vincenzo S. Gilberto Vincenzo S. Gilberto Mark D. Zabel Mark D. Zabel Mark D. Zabel Julie A. Moreno Julie A. Moreno Julie A. Moreno Julie A. Moreno |
| author_sort | Arielle J. D. Hay |
| collection | DOAJ |
| description | Mesenchymal stromal cells (MSCs) are an intriguing avenue for the treatment of neurological disorders due to their ability to migrate to sites of neuroinflammation and respond to paracrine signaling in those sites by secreting cytokines, growth factors, and other neuromodulators. We potentiated this ability by stimulating MSCs with inflammatory molecules, improving their migratory and secretory properties. We investigated the use of intranasally delivered adipose-derived MSCs (AdMSCs) in combating prion disease in a mouse model. Prion disease is a rare, lethal neurodegenerative disease that results from the misfolding and aggregation of the prion protein. Early signs of this disease include neuroinflammation, activation of microglia, and development of reactive astrocytes. Later stages of disease include development of vacuoles, neuronal loss, abundant aggregated prions, and astrogliosis. We demonstrate the ability of AdMSCs to upregulate anti-inflammatory genes and growth factors when stimulated with tumor necrosis factor alpha (TNFα) or prion-infected brain homogenates. We stimulated AdMSCs with TNFα and performed biweekly intranasal deliveries of AdMSCs on mice that had been intracranially inoculated with mouse-adapted prions. At early stages in disease, animals treated with AdMSCs showed decreased vacuolization throughout the brain. Expression of genes associated with Nuclear Factor-kappa B (NF-κB) and Nod-Like Receptor family pyrin domain containing 3 (NLRP3) inflammasome signaling were decreased in the hippocampus. AdMSC treatment promoted a quiescent state in hippocampal microglia by inducing changes in both number and morphology. Animals that received AdMSCs showed a decrease in both overall and reactive astrocyte number, and morphological changes indicative of homeostatic astrocytes. Although this treatment did not prolong survival or rescue neurons, it demonstrates the benefits of MSCs in combatting neuroinflammation and astrogliosis. |
| first_indexed | 2024-04-09T13:13:58Z |
| format | Article |
| id | doaj.art-dc6fcc63d1044053ab6439989e38bd95 |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-04-09T13:13:58Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-dc6fcc63d1044053ab6439989e38bd952023-05-12T05:39:36ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2023-05-011710.3389/fnins.2023.11584081158408Intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion diseaseArielle J. D. Hay0Arielle J. D. Hay1Amanda S. Latham2Amanda S. Latham3Genova Mumford4Genova Mumford5Amelia D. Hines6Amelia D. Hines7Sydney Risen8Sydney Risen9Elizabeth Gordon10Connor Siebenaler11Connor Siebenaler12Vincenzo S. Gilberto13Vincenzo S. Gilberto14Mark D. Zabel15Mark D. Zabel16Mark D. Zabel17Julie A. Moreno18Julie A. Moreno19Julie A. Moreno20Julie A. Moreno21Prion Research Center, Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesBrain Research Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesPrion Research Center, Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesBrain Research Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesBrain Research Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesPrion Research Center, Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesPrion Research Center, Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesBrain Research Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesPrion Research Center, Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesCenter for Healthy Aging, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesPrion Research Center, Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesDepartment of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesBrain Research Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesCenter for Healthy Aging, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United StatesMesenchymal stromal cells (MSCs) are an intriguing avenue for the treatment of neurological disorders due to their ability to migrate to sites of neuroinflammation and respond to paracrine signaling in those sites by secreting cytokines, growth factors, and other neuromodulators. We potentiated this ability by stimulating MSCs with inflammatory molecules, improving their migratory and secretory properties. We investigated the use of intranasally delivered adipose-derived MSCs (AdMSCs) in combating prion disease in a mouse model. Prion disease is a rare, lethal neurodegenerative disease that results from the misfolding and aggregation of the prion protein. Early signs of this disease include neuroinflammation, activation of microglia, and development of reactive astrocytes. Later stages of disease include development of vacuoles, neuronal loss, abundant aggregated prions, and astrogliosis. We demonstrate the ability of AdMSCs to upregulate anti-inflammatory genes and growth factors when stimulated with tumor necrosis factor alpha (TNFα) or prion-infected brain homogenates. We stimulated AdMSCs with TNFα and performed biweekly intranasal deliveries of AdMSCs on mice that had been intracranially inoculated with mouse-adapted prions. At early stages in disease, animals treated with AdMSCs showed decreased vacuolization throughout the brain. Expression of genes associated with Nuclear Factor-kappa B (NF-κB) and Nod-Like Receptor family pyrin domain containing 3 (NLRP3) inflammasome signaling were decreased in the hippocampus. AdMSC treatment promoted a quiescent state in hippocampal microglia by inducing changes in both number and morphology. Animals that received AdMSCs showed a decrease in both overall and reactive astrocyte number, and morphological changes indicative of homeostatic astrocytes. Although this treatment did not prolong survival or rescue neurons, it demonstrates the benefits of MSCs in combatting neuroinflammation and astrogliosis.https://www.frontiersin.org/articles/10.3389/fnins.2023.1158408/fullmicrogliaastrocytesprioninflammationcytokinesmesenchymal stromal cells |
| spellingShingle | Arielle J. D. Hay Arielle J. D. Hay Amanda S. Latham Amanda S. Latham Genova Mumford Genova Mumford Amelia D. Hines Amelia D. Hines Sydney Risen Sydney Risen Elizabeth Gordon Connor Siebenaler Connor Siebenaler Vincenzo S. Gilberto Vincenzo S. Gilberto Mark D. Zabel Mark D. Zabel Mark D. Zabel Julie A. Moreno Julie A. Moreno Julie A. Moreno Julie A. Moreno Intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion disease Frontiers in Neuroscience microglia astrocytes prion inflammation cytokines mesenchymal stromal cells |
| title | Intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion disease |
| title_full | Intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion disease |
| title_fullStr | Intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion disease |
| title_full_unstemmed | Intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion disease |
| title_short | Intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion disease |
| title_sort | intranasally delivered mesenchymal stromal cells decrease glial inflammation early in prion disease |
| topic | microglia astrocytes prion inflammation cytokines mesenchymal stromal cells |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2023.1158408/full |
| work_keys_str_mv | AT ariellejdhay intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT ariellejdhay intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT amandaslatham intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT amandaslatham intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT genovamumford intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT genovamumford intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT ameliadhines intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT ameliadhines intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT sydneyrisen intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT sydneyrisen intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT elizabethgordon intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT connorsiebenaler intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT connorsiebenaler intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT vincenzosgilberto intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT vincenzosgilberto intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT markdzabel intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT markdzabel intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT markdzabel intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT julieamoreno intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT julieamoreno intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT julieamoreno intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease AT julieamoreno intranasallydeliveredmesenchymalstromalcellsdecreaseglialinflammationearlyinpriondisease |